Clinical Medications Development for Opiate Addiction: Focus on Nonopioids and Opioid Antagonists for the Amelioration of Opiate Withdrawal Symptoms and Relapse Prevention

O'Brien, 1996, Myths about the treatment of addiction, Lancet, 347, 237, 10.1016/S0140-6736(96)90409-2 Mendelson, 1996, Management of cocaine abuse and dependence, N. Eng. J. Med., 334, 965, 10.1056/NEJM199604113341507 McLellan, 1993, The effects of psychosocial services in substance abuse treatment, J. Am. Med. Assoc., 269, 1953, 10.1001/jama.1993.03500150065028 Herman, 1995, The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal: Medication development issues for opiate addiction, Neuropsychopharmacology, 13, 269, 10.1016/0893-133X(95)00140-9 Kreek, 1997, Clinical update of opioid agonist and partial agonist medications for the maintenance treatment of opiate addiction, Semin. Neurosci., 9, 10.1006/smns.1997.0114 Kleber, 1982, The treatment of narcotic withdrawal: a historical review, J. Clin. Psychiatr., 43, 30 Mattick, 1996, Are detoxification programmes effective?, Lancet, 347, 97, 10.1016/S0140-6736(96)90215-9 Ball, 1991 Nestler, 1997, Molecular mechanisms underlying opiate addiction: implications for medications development, Semin. Neurosci., 9, 10.1006/smns.1997.0109 Aghajanian, 1982, Central noradrenergic neurons: a locus for the functional interplay between alpha-2-adrenoreceptors and opiate receptors, J. Clin. Psychiatr., 43, 20 Gold, 1993, Opiate addiction and the locus coeruleus. The clinical utility of clonidine, naltrexone, methadone, and buprenorphine. Recent Advances in Addictive Disorders, Psychiatr. Clin. North Am., 16, 61, 10.1016/S0193-953X(18)30190-4 Roth, 1982, Clonidine suppression of noradrenergic hyperactivity during morphine withdrawal by clonidine: Biochemical studies in rodents and primates, J. Clin. Psychiatr., 43, 42 Jaffe, 1995, Pharmacological treatment of opioid dependence: current techniques and new findings, Psychiatr. Ann., 25, 369, 10.3928/0048-5713-19950601-09 Aston-Jones, 1993, Opiates influence locus coeruleus neurons by potent indirect and direct actions Gold, 1978, Clonidine blocks acute opiate withdrawal symptoms, Lancet, 1, 599, 10.1016/S0140-6736(78)92823-4 Gold, 1980, Opiate withdrawal using clonidine: A safe, effective, and rapid nonopiate treatment, JAMA, 243, 343, 10.1001/jama.1980.03300300021018 Charney, 1981, The clinical use of clonidine in abrupt withdrawal from methadone, Arch. Gen. Psychiatr., 38, 1273, 10.1001/archpsyc.1981.01780360089010 Uhde, 1980, Clonidine suppresses the opiate abstinence syndrome without clonidine-withdrawal symptoms: A blind inpatient study, Psychiatr. Res., 2, 37, 10.1016/0165-1781(80)90005-0 Jasinski, 1985, Clonidine in morphine withdrawal. Differential effects on signs and symptoms, Arch. Gen. Psychiatr., 42, 1063, 10.1001/archpsyc.1985.01790340041006 Ghodse, 1994, Clonidine is not a useful adjunct to methadone gradual detoxification in opioid addiction, Br. J. Psychiatr., 165, 370, 10.1192/bjp.165.3.370 Kahn, 1997, Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital, Drug Alcohol Depend., 44, 57, 10.1016/S0376-8716(96)01316-6 Washton, 1981, Clonidine in opiate withdrawal: Review and appraisal of clinical findings, Pharmacotherapy, 1, 140, 10.1002/j.1875-9114.1981.tb03561.x Riordan, 1980, Rapid opiate detoxification with clonidine and naloxone, Lancet, 1, 1079, 10.1016/S0140-6736(80)91516-0 Charney, 1982, Clonidine and naltrexone: A safe, effective, and rapid treatment of abrupt withdrawal from methadone therapy, Arch. Gen. Psychiatr., 39, 1327, 10.1001/archpsyc.1982.04290110077013 Charney, 1986, The combined use of clonidine and naltrexone as a rapid, safe, and effective treatment of abrupt withdrawal from methadone, Am. J. Psychiatr., 143, 831, 10.1176/ajp.143.7.831 Gerra, 1995, Clonidine and opiate receptor antagonists in the treatment of heroin addiction, J. Subst. Abuse Treat., 12, 35, 10.1016/0740-5472(94)00077-8 Kleber, 1987, Clonidine and naltrexone in the outpatient treatment of heroin withdrawal, Am. J. Drug Alcohol Abuse, 13, 1, 10.3109/00952998709001497 Marjamäki, 1993, Use of recombinant human alpha-2-adrenoreceptors to characterize subtype selectivity of antagonist binding, Eur. J. Pharmacol., 246, 219, 10.1016/0922-4106(93)90034-7 Uhlen, 1991, Delineation of rat kidney alpha-2A and alpha 2B-adrenoreceptors with [3, Eur. J. Pharmacol., 202, 235 Arnsten, 1988, The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive adverse effects: Evidence for alpha-2 receptor subtypes, J. Neurosci., 8, 4287, 10.1523/JNEUROSCI.08-11-04287.1988 Shearman, 1980, Effectiveness of lofexidine in blocking morphine-withdrawal signs in the rat, Pharm. Biochem. Behav., 12, 573, 10.1016/0091-3057(80)90191-4 Gold, 1981, Opiate detoxification with lofexidine, Drug Alcohol Depend., 8, 307, 10.1016/0376-8716(81)90040-5 Washton, 1982, Lofexidine in abrupt methadone withdrawal, Psychopharmacol. Bull., 18, 220 Washton, 1983, Opiate withdrawal using lofexidine, a clonidine analogue with fewer side effects, J. Clin. Psychiatr., 44, 335 Bearn, 1996, Randomised double-blind comparison of lofexidine and methadone in the in-patient treatment of opiate withdrawal, Drug Alcohol Depend., 43, 87, 10.1016/S0376-8716(96)01289-6 Gabilondo, 1994, Mu-opioid receptor and alpha 2-adrenoreceptor agonist binding sites in the postmortem brain of heroin addicts, Psychopharmacol. Berlin, 115, 135, 10.1007/BF02244763 Gerra, 1994, Alpha-2-adrenoreceptor sensitivity in heroin addicts with and without previous attention deficit disorder/hyperactivity and conduct disorder, Neuropsychobiology, 30, 15, 10.1159/000119129 Inturrisi, 1997, Preclinical evidence for a role of glutamatergic systems in opioid tolerance and dependence, Semin. Neurosci., 9, 10.1006/smns.1997.0111 Haigler, 1994, NMDA receptor antagonists: neurotoxicity evaluation, Psychopharmacol. Bull., 30, 525 Auer, 1994, The nature and time course of neuronal vacuolation induced by the NMDA antagonist MK-801, Acta. Neuropathol. (Berlin, 87, 1, 10.1007/BF00386248 Olney, 1989, Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs, Science, 244, 1360, 10.1126/science.2660263 Rasmussen, 1991, NMDA receptor antagonists suppress behaviors but not norepinephrine turnover or locus coeruleus unit activity induced by opiate withdrawal, Eur. J. Pharmacol., 197, 9, 10.1016/0014-2999(91)90358-W Koek, 1990, Selective blockade ofNd, J. Pharmacol. Exp. Ther., 252, 349 Herrling, 1994, D-CPPene (SDZ EAA 494), A competitive NMDA antagonist: results from animal models and first results in humans, Neuropsychopharmacology, 10, 591S Vaupel, 1995, Nitric oxide synthase inhibitors: Preclinical studies of potential use for treatment of opioid withdrawal, Neuropsychopharmacology, 13, 315, 10.1016/0893-133X(95)00138-4 Chen, 1992, Open channel block ofNd, J. Neurosci., 12, 4427, 10.1523/JNEUROSCI.12-11-04427.1992 McQuay, 1994, Dextromethorphan for the treatment of neuropathic pain: A double-blind randomised controlled crossover trial with integral n-of-1 design, Pain, 59, 127, 10.1016/0304-3959(94)90056-6 Nelson, 1997, High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia, Neurology, 48, 1212, 10.1212/WNL.48.5.1212 Koyuncuoglu, 1990, The treatment of heroin addicts with dextromethorphan: A double-blind comparison of dextromethorphan with chlorpromazine, Int. J. Clin. Pharmacol. Ther. Toxicol., 28, 147 Rosen, 1996, A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal, Eur. J. Pharmacol., 307, 251, 10.1016/0014-2999(96)00249-X M. I. Rosen, F. A. Hameedi, H. R. Pearsall, T. R. Kosten, 1996b, The effect of lamotrigine on naloxone-precipitated opiate withdrawal Childress, 1992, Classically conditioned factors in drug dependence, 56 Pulvirenti, 1997, Dextromethorphan reduces intravenous cocaine self-administration in the rat, Eur. J. Pharmacol., 321, 279, 10.1016/S0014-2999(96)00970-3 Przegalinski, 1996, Anticonflict effects of a competitive NMDA receptor antagonist and a partial agonist at strychnine-insensitive glycine receptors, Pharm. Biochem. Behav., 54, 73, 10.1016/0091-3057(95)02157-4 Popik, 1996, The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence, Pharmacol. Biochem. Behav., 53, 791, 10.1016/0091-3057(95)02163-9 Zeise, 1993, Acamprosate (calcium acetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: Possible involvement of excitatory amino acid receptors, Eur. J. Pharmacol., 231, 47, 10.1016/0014-2999(93)90682-8 Sass, 1996, Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence, Arch. Gen. Psychiatr., 53, 673, 10.1001/archpsyc.1996.01830080023006 Litten, 1996, Pharmacotherapies for alcohol problems: A review of research with focus on developments since 1991, Alcohol Clin. Exp. Res., 20, 859, 10.1111/j.1530-0277.1996.tb05264.x Costall, 1992, Profile or action of a novel 5-hydroxytryptamine1A receptor ligand E-4424 to inhibit aversive behavior in the mouse, rat and marmoset, J. Pharmacol. Exp. Ther., 262, 90 Herman, 1981, Ascending endorphinergic inhibition of distress vocalization, Science, 211, 1060, 10.1126/science.7466377 Ratey, 1991, Buspirone treatment of aggression and anxiety in mentally retarded patients: A multiple-baseline, placebo lead-in study, J. Clin. Psychiatr., 52, 159 Delle-Chiaie, 1995, Assessment of the efficacy of buspirone in patients affects by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: A placebo-controlled, double-blind study, J. Clin. Psychopharmacol., 15, 12, 10.1097/00004714-199502000-00003 O'Hanlon, 1991, Review of buspirone's effects on human performance and related variables, Eur. Neuropsychopharmacol., 1, 489, 10.1016/0924-977X(91)90002-C M. D. Aceto, E. R. Bowman, L. S. Harris, E. L. May, 1992, Dependence studies of new compounds in the rhesus monkey and mouse (1991). Problems of Drug Dependence 1991, Proceedings of the 53rd Annual Scientific Meeting, L. Harris, 554, 555, The Committee on Problems of Drug Dependence, Inc, Rockville, MD Balster, 1990, Abuse potential of buspirone and related drugs, J. Clin. Psychopharmacol., 10, 31S, 10.1097/00004714-199006001-00007 Batki, 1990, Buspirone in drug users with AIDS or AIDS-related complex, J. Clin. Psychopharmacol., 10, 111S, 10.1097/00004714-199006001-00018 Curzon, 1991, Effects of tryptophan and of 5-hydroxytryptamine receptor subtype agonists on feeding, Adv. Exp. Med. Biol., 294, 377, 10.1007/978-1-4684-5952-4_35 Kranzler, 1996, Evaluation and treatment of anxiety symptoms and disorders in alcoholics, J. Clin. Psychiatr., 57, 12 Knapp, 1992, Effects of gepirone on ethanol consumption, exploratory behavior, and motor performance in rats, Drug Dev. Res., 26, 319, 10.1002/ddr.430260310 Tomkins, 1994, Low doses of the 5-HT1A, Psychopharmacology, 115, 173, 10.1007/BF02244769 Tollefson, 1992, Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone), J. Clin. Psychopharmacol., 12, 19, 10.1097/00004714-199202000-00004 Cinciripini, 1995, A placebo-controlled evaluation of the effects of buspirone on smoking cessation: Differences between high- and low-anxiety smokers, J. Clin. Psychopharmacol., 15, 182, 10.1097/00004714-199506000-00006 Maremmani, 1995, Fluoxetine improves outcome in addicted patients treated with opioid antagonists, Am. J. Addictions, 4, 267 Murphy, 1988, Effects of fluoxetine on the intragastric self-administration of ethanol in the alcohol-preferring P line of rats, Alcohol, 5, 283, 10.1016/0741-8329(88)90066-3 Hollister, 1978, Clinical evaluation of naltrexone treatment of opiate-dependent individuals: Report of the National Research Council Committee on Clinical Evaluation of Narcotic Antagonists, Arch. Gen. Psychiatr., 35, 335, 10.1001/archpsyc.1978.01770270085008 Stanfa, 1994, Cholecystokinin and morphine analgesia: variations on a theme, TiPS, 15, 65 Faris, 1983, Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia, Science, 219, 310, 10.1126/science.6294831 Dourish, 1988, Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by the cholecystokinin antagonist L-364,718, Eur. J. Pharmacol., 147, 469, 10.1016/0014-2999(88)90183-5 Dourish, 1990, The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat, Eur. J. Pharmacol., 176, 35, 10.1016/0014-2999(90)90129-T Watkins, 1984, Potentiation of opiate analgesia and apparent reversal of morphine tolerance by proglumide, Science, 224, 395, 10.1126/science.6546809 Wiesenfeld-Hallin, 1990, PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes, Proc. Natl. Acad. Sci. USA, 87, 7105, 10.1073/pnas.87.18.7105 Xu, 1996, L-740,093, a new antagonist of the CCK-B receptor, potentiates the antinociceptive effect of morphine: Electrophysiological and behavioural studies, Neuropeptides, 30, 203, 10.1016/S0143-4179(96)90088-8 O'Neill, 1990, Blockade of CCK-B receptors by L-365,260 induces analgesia in the squirrel monkey, Brain Res., 534, 287, 10.1016/0006-8993(90)90141-W Zhou, 1993, Increased release of immunoreactive cholecystokinin octapeptide by morphine and potentiation of mu-opioid analgesia by CCKB, Eur. J. Pharmacol., 234, 147, 10.1016/0014-2999(93)90948-H Panerai, 1987, Dissociation of tolerance and dependence to morphine: A possible role of cholecystokinin, Brain Res., 410, 52, 10.1016/S0006-8993(87)80019-7 Barber, 1989, The role of CCK caerulein, and CCK antagonists in nociception, Pain, 39, 307, 10.1016/0304-3959(89)90045-6 Maldonado, 1994, Effects induced by BC 264, a selective agonist of CCK-B receptors, on morphine-dependent rats, Pharmacol. Biochem. Behav., 48, 363, 10.1016/0091-3057(94)90539-8 Hoffmann, 1994, The CCK-B receptor antagonist CI 988 reverses tolerance to morphine in rats, NeuroReport, 5, 2565, 10.1097/00001756-199412000-00040 Tiseo, 1993, Attenuation and reversal of morphine tolerance by the competitiveNd, J. Pharmacol. Exp. Ther., 264, 1090 Hendrie, 1993, The effects of CCKA and CCKB antagonists on activity in the black/white exploration model of anxiety in mice, Physiol. Behav., 54, 689, 10.1016/0031-9384(93)90077-S Powell, 1991, Evaluation of the effects of PD 134308 (CI-988), a CCK-B antagonist, on the punished responding of squirrel monkeys, Neuropeptides, 19, 75, 10.1016/0143-4179(91)90085-W Bradwejn, 1994, The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder, Arch. Gen. Psychiatr., 51, 486, 10.1001/archpsyc.1994.03950060050005 Kramer, 1995, A placebo-controlled trial of L-365,260, a CCKB antagonist in panic disorder, Biol. Psychiatr., 37, 462, 10.1016/0006-3223(94)00190-E Tokar, 1975, Determining what heroin means to heroin addicts, Dis. Nervous System, 36, 77 Livingstone, 1988, Amelioration of naloxone-precipitated opioid withdrawal symptoms by peripheral administration of the enkephalinase inhibitor acetorphan, Psychopharmacology, 94, 540, 10.1007/BF00212852 Hartmann, 1991, Comparison of acetorphan with clonidine for opiate withdrawal symptoms, Am. J. Psychiatr., 148, 627, 10.1176/ajp.148.5.627 Roge, 1993, The enkephalinase inhibitor, acetorphan, in acute diarrhoea. A double-blind, controlled clinical trial versus loperamide, Scand. J. Gastroenterol., 28, 352, 10.3109/00365529309090255 Yaksh, 1991, Effects of [Nll, J. Pharmacol. Exp. Ther., 256, 1033 Roques, 1995, Dual inhibitors of enkephalin-degrading enzymes (neutral endopeptidase 24.11 and aminopeptidase N) as potential new medications in the management of pain and opioid addiction, NIDA Res. Monogr., 147, 104 Fishman, 1973, Disposition of naloxone in normal and narcotic-dependent men, J. Pharmacol. Exp. Ther., 187, 575 Resnick, 1978, Naltrexone in the treatment of opiate dependence, 321 Resnick, 1974, Studies of EN-1639A (naltrexone): A new narcotic antagonist, Am. J. Psychiatr., 131, 646, 10.1176/ajp.131.6.646 O'Brien, 1978, Clinical pharmacology of narcotic antagonists, Annals of NY Academy of Sciences, 311, 232, 10.1111/j.1749-6632.1978.tb16779.x Martin, 1973, Naltrexone, an antagonist for the treatment of heroin dependence, Arch. Gen. Psychiatr., 28, 784, 10.1001/archpsyc.1973.01750360022003 Lee, 1988, Duration of occupancy of opiate receptors by naltrexone, J. Nuclear Med., 29, 1207 Loimer, 1991, Technique for greatly shortening the transition from methadone to naltrexone maintenance of patients addicted to opiates, Am. J. Psychiatr., 148, 933, 10.1176/ajp.148.7.933 Brewer, 1988, Opioid withdrawal and naltrexone induction in 48–72 hours with minimal drop-out, using a modification of the naltrexone-clonidine technique, Br. J. Psychiatr., 153, 340, 10.1192/bjp.153.3.340 Greenstein, 1984, Naltrexone: a clinical perspective, J. Clin. Psychiatr., 45, 25 Washton, 1984, Naltrexone in addicted business executives and physicians, J. Clin. Psychiatr., 45, 39 Cornish, 1997, Naltrexone pharmacotherapy for opioid dependent federal probationers, J. Substance Abuse Treatment, 14, 1, 10.1016/S0740-5472(97)00020-2 Gonzalez, 1988, Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence, Drugs, 35, 192, 10.2165/00003495-198835030-00002 H. Kranzler, 1996, Oral presentation—American College of Neuropsychopharmacology, San Juan, Puerto Rico Maggio, 1985, Naltrexone and human eating behavior: A dose-ranging inpatient trial in moderately obese men, Brain Res. Bull., 14, 657, 10.1016/0361-9230(85)90115-7 Hahn, 1975, Narcotic antagonists. 4. Carbon-6 derivatives of N-substituted noroxymorphones as narcotic antagonists, J. Med. Chem., 18, 259, 10.1021/jm00237a008 Dixon, 1986, Nalmefene: Intravenous safety and kinetics of a new opioid antagonist, Clin. Pharmacol. Ther., 39, 49, 10.1038/clpt.1986.9 Gal, 1986, Prolonged blockade of opioid effect with oral nalmefene, Clin. Pharmacol. Ther., 40, 537, 10.1038/clpt.1986.220 Konieczko, 1988, Antagonism of morphine-induced respiratory depression with nalmefene, Br. J. Anaesth., 61, 318, 10.1093/bja/61.3.318 Glass, 1994, Comparison of potency and duration of action nalmefene and naloxone, Anesth. Analg., 78, 536, 10.1213/00000539-199403000-00021 Barsan, 1989, Duration of antagonistic effects of nalmefene and naloxone in opiate-induced sedation for emergency department procedures, Am. J. Emerg. Med., 7, 155, 10.1016/0735-6757(89)90128-9 Fudala, 1991, Human pharmacology and abuse potential of nalmefene, Clin. Pharmacol. Ther., 49, 300, 10.1038/clpt.1991.32 Mason, 1994, A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence, Alcoholism: Clin. Exp. Res., 18, 1162, 10.1111/j.1530-0277.1994.tb00098.x Ulm, 1995, Opiates and alcohol self-administration in animals, J. Clin. Psychiatr., 56, 5 J. Volpicelli, A. Alterman, M. Hayashida, L. Muentz, C. P. O'Brien, Naltrexone and the treatment of alcohol dependence, Opioids, Bulimia and Alcoholism, L. D. Reid, 195, 214, Springer-Verlag, New York Volpicelli, 1992, Naltrexone in the treatment of alcohol dependence, Arch. Gen. Psychiatr., 49, 876, 10.1001/archpsyc.1992.01820110040006 O'Malley, 1992, Naltrexone and coping skills therapy for alcohol dependence, Arch. Gen. Psychiatr., 49, 881, 10.1001/archpsyc.1992.01820110045007